Literature DB >> 10828666

Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens.

I T Köksal1, F Ozcan, T C Kadioglu, T Esen, I Kiliçaslan, M Tunç.   

Abstract

OBJECTIVE: The grade of the prostate cancer is an important factor in defining prognosis and deciding on treatment. In this study, we compared the Gleason score determined by 18-gauge core needle biopsies with both the Gleason score and pathological staging of the radical prostatectomy specimens. PATIENTS AND METHODS: Between July 1992 and September 1998, we performed 144 radical retropubic prostatectomies for clinically localized prostatic carcinoma, after a negative frozen section in bilateral pelvic lymphadenectomy in all cases. Ten patients with pathologic stage T1a and T1b were excluded. The final study group consisted of 134 patients, all of whom had been diagnosed with adenocarcinoma by transrectal needle biopsies with an 18-gauge automated spring-loaded biopsy gun. No patients received neoadjuvant therapy, including androgen deprivation and radiation therapy. All patients had a designated Gleason score on the needle biopsy and prostatectomy specimens.
RESULTS: We found that grading error was greatest with well-differentiated (Gleason score 2-4) tumors, The accuracy was 15% for Gleason score 2-4 on needle biopsy. Of the 113 evaluable patients with Gleason score 5-7 on needle biopsy, 110 (97%) were graded correctly. All of the Gleason score 8-10 on needle biopsy was graded correctly. But only 1 patient in our series had Gleason score 8 on needle biopsy. Twenty-seven (25%) of 110 patients with a biopsy grade of Gleason score <7 had the cancer upgraded to 7. Of patients with both Gleason score <7 in the needle biopsy and Gleason score 7 in the prostatectomy specimen, only 3 (11%) had tumor confined to the prostate.
CONCLUSION: The potential for grading error is greatest with well-differentiated tumors and of patients with both Gleason scores <7 in the needle biopsy and Gleason score 7 in the prostatectomy specimen, only 11% had tumor confined to the prostate. This effects treatment policy, especially for watchful waiting criteria.

Entities:  

Mesh:

Year:  2000        PMID: 10828666     DOI: 10.1159/000020216

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  16 in total

Review 1.  [MRI of the prostate].

Authors:  D Nörenberg; O Solyanik; B Schlenker; G Magistro; B Ertl-Wagner; D A Clevert; C Stief; M F Reiser; M D'Anastasi
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 2.  Value of multiparametric MRI in the work-up of prostate cancer.

Authors:  F Cornud; N B Delongchamps; P Mozer; F Beuvon; A Schull; N Muradyan; M Peyromaure
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

3.  [Problems, objective, and substance of early detection of prostate cancer].

Authors:  C Börgermann; H Loertzer; P Hammerer; P Fornara; M Graefen; H Rübben
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

Review 4.  Focal therapy in prostate cancer: modalities, findings and future considerations.

Authors:  Uri Lindner; John Trachtenberg; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

Review 5.  [Trends in prostate biopsy interpretation].

Authors:  J Köllermann; G Sauter
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 6.  [PSA--Quo vadis?].

Authors:  C Börgermann; H Loertzer; H-J Luboldt; P Hammerer; P Fornara; M Graefen; H Rübben
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

7.  Use of two gene panels for prostate cancer diagnosis and patient risk stratification.

Authors:  Kefeng Xiao; Jinan Guo; Xuhui Zhang; Xiaoyan Feng; Heqiu Zhang; Zhiqiang Cheng; Heather Johnson; Jenny L Persson; Lingwu Chen
Journal:  Tumour Biol       Date:  2016-01-28

8.  Recent advances in magnetic resonance imaging of prostate cancer.

Authors:  Nathan Lawrentschuk; Uri Lindner
Journal:  F1000 Med Rep       Date:  2010-12-08

9.  Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging.

Authors:  Maria Inês Novis; Ronaldo Hueb Baroni; Luciana Mendes de Oliveira Cerri; Romulo Loss Mattedi; Carlos Alberto Buchpiguel
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Can diffusion-weighted magnetic resonance imaging predict a high Gleason score of prostate cancer?

Authors:  Katsumi Shigemura; Nozomu Yamanaka; Masuo Yamashita
Journal:  Korean J Urol       Date:  2013-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.